Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | CPS1 | P31327 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193171 | 0.84 | RARB (0.43) | MAOBMAOACPS1ALDH1A1 | |
| SCHEMBL364906 | 0.83 | CPS1 (0.45) | MAOBCPS1ALDH1A1HPGD | |
| SCHEMBL29639738 | 0.81 | ALDH1A1 (0.65) | MAOBMAOACPS1ALDH1A1CYP3A4 | |
| SCHEMBL531399 | 0.81 | ALDH1A1 (0.65) | MAOBMAOACPS1ALDH1A1CYP3A4 | |
| SCHEMBL17420671 | 0.80 | ALDH1A1 (0.58) | MAOBMAOACPS1ALDH1A1CYP3A4 | |
| SCHEMBL30628292 | 0.80 | ALDH1A1 (0.58) | MAOBMAOACPS1ALDH1A1CYP3A4 | |
| SCHEMBL15920708 | 0.79 | CA12 (0.46) | MAOBALDH1A1HPGD | |
| SCHEMBL2279929 | 0.79 | MAOB (0.55) | MAOBMAOACPS1ALDH1A1CYP3A4 | |
| SCHEMBL17766955 | 0.77 | MAOB (0.54) | MAOBMAOACPS1ALDH1A1CYP3A4 | |
| SCHEMBL14356128 | 0.77 | MAOB (0.66) | MAOBMAOACPS1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456156-B2 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1404685-B1 | ARYL BORONIC ACIDS FOR TREATING OBESITY | GENZYME CORP (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060128663-A1 | Aryl boronate functionalized polymers for treating obesity | GENZYME CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060128664-A1 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| US-7049304-B2 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2006-05-23 | — | — | US | disclosed |
| US-7041280-B2 | Aryl boronate functionalized polymers for treating obesity | GENZYME CORPORATION (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050107336-A1 | Aryl boronic acids for treating obesity | HOLMES-FARLEY STEPHEN R (US) | 2005-05-19 | — | — | US | disclosed |
| US-6858592-B2 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1404686-A1 | ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY | Geltex Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404685-A1 | ARYL BORONIC ACIDS FOR TREATING OBESITY | Geltex Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030064963-A1 | Aryl boronic acids for treating obesity | GELTEX PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030059399-A1 | Aryl boronate functionalized polymers for treating obesity | GELTEX PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003002570-A1 | ARYL BORONIC ACIDS FOR TREATING OBESITY | GENZYME CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002571-A1 | ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY | GENZYME CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128664-A1 | Aryl boronic acids for treating obesity | FFAR3, NR1H4, NR1H3 | MAOB 1094/4885MAOA 1381/4885CPS1 950/4885 |
| US-20030059399-A1 | Aryl boronate functionalized polymers for treating obesity | CEL, AHR, LIPE | MAOB 48/4885MAOA 123/4885CPS1 1632/4885 |
| US-20050107336-A1 | Aryl boronic acids for treating obesity | FFAR3, NR1H3, NR1H4 | MAOB 1132/4885MAOA 1376/4885CPS1 923/4885 |
| US-20030064963-A1 | Aryl boronic acids for treating obesity | FFAR3, FFAR1, NR1H3 | MAOB 1497/4885MAOA 2271/4885CPS1 650/4885 |
| US-20060128663-A1 | Aryl boronate functionalized polymers for treating obesity | CEL, AHR, LIPE | MAOB 52/4885MAOA 171/4885CPS1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.